ATXI
AVENUE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.43
+0.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +50.5%
- EBIT
- +51.3%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +71.9%
- EBIT
- +70.9%
- Net income
- +75.0%
- EPS
- -3.3%
- Free cash flow
- +79.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026